West Cancer Center

« back to all trials

RENAL CELL: METASTATIC: 2nd/3rd Line: MK-6482-013

Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma

Title

Merck MK6482-013 (Renal cell belzutifan)

Study Title

Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma

Site Link

NCT04489771

Malignancy

Renal cell carcinoma, Kidney cancer, clear cell, RCC

Stage

Stage 4

Disease Setting

Metastatic/Palliative

Line Of Therapy

2nd, 3rd, or 4th

Investigational Agent

Belzutifan

Drug Class

HIF-2a inhibitor

Dan Vaena, MD

Sponsor

Merck Sharp & Dohme Corp

Phase

Phase 2

Status

Closed to Accrual

Key Eligibility Criteria

Key Eligibility Criteria Details

Histologically confirmed diagnosis of locally advanced/metastatic RCC with clear cell component
Has had disease progression on or after having received 1st line systemic treatment for RCC with CTLA4+PD1 or VEGF-TKI+PD1
No more than 3 prior lines of therapy
KPS >/= 70
No requirement for supplemental oxygen at baseline
No prior cancer within 3 years
No known CNS mets
No significant cardiac disease
No receipt of GCSF or EPO within 28 days prior to first dose
No known HBV/HCV/HIV

Objective

Assessment Frequency

Assessment Frequency 2

Assessment Frequency Link

Path

Clear cell component

Dosing Frequency

Control Agents

Study Protocol

Randomized

Yes